• Skip to primary navigation
  • Skip to main content
  • Skip to footer
Exopharm

Exopharm

  • Home
  • Products
  • Partnering
  • Science
  • Resources
    • ASX Announcements
    • Investor Information
    • News & Articles
    • Careers
  • About Us
    • Our Values
    • Our Story
    • Our Team
    • Board of Directors
  • Contact
Exopharm

Refreshing Medicine, Today

Exopharm (ASX: EX1) is a clinical stage company at the forefront of developing transformative medicines based upon exosomes (EVs). Our mission is to be a global leader in EV-based therapeutics.

Products

Leaders in the development of transformative EV-based medicines

Exopharm is developing and commercialising EVs as therapeutics –
Engineered EVs (EEVs) as delivery vehicles for active cargo drugs to treat infectious diseases, neurological diseases and cancer; and
Naïve EVs (NEVs) from stem cells and platelets to treat selected conditions such as osteoarthritis and chronic and acute injuries

Partnering

 

Partner with Exopharm to meet your EV medicine goals

EVs can:

  • Solve delivery problems with existing ‘stranded assets’
  • Target loaded drugs to specific cell types (i.e. confer tropism)
  • Deliver drugs across biological barriers, including the blood brain barrier

Science

EVs (also known as exosomes) harness the powerful natural ability of EVs to efficiently target cells and transfer selected materials into cells and across barriers. These natural yet powerful properties of EVs are now seen as a better way to deliver nucleic acid and other medicines.

Exopharm is advancing EV medicines in two main areas: engineered EVs as tools to deliver active drugs as precision medicines, and naïve EVs, or unaltered EVs, from stem cells and other cells as regenerative medicines.

Exopharm’s LEAP manufacturing technology provides access to large quantities of high-purity EVs for research and clinical uses.

Resources

 

Exopharm is a publicly traded company on the Australian Securities Exchange under code ASX:EX1.

Visit our Resources section for ASX announcements, investor information, news and articles.

Under News and Articles, access more information about EVs, news, whitepapers and opinion articles. Also find links to past talks and webinars.

About us

An experienced and dedicated team
Founded in 2013 by Dr Ian Dixon on the LEAP Technology, Exopharm has built a highly skilled team with broad manufacturing, scientific and commercial expertise. Our success would not be possible without the exceptional minds working together behind the scenes with a range of capabilities across specialised areas.


Latest News

  • The Life of Science – Aislinn
    The Life of Science – Aislinn
  • Exopharm preps for great LEAP forward as world catches onto exosome promise
    Exopharm preps for great LEAP forward as world catches onto exosome promise
  • Early Careers in Science Webinar
    Early Careers in Science Webinar
  • Exopharm presents at BIO CEO & Investor Digital Conference
    Exopharm presents at BIO CEO & Investor Digital Conference
  • The Life of Science – Sam
    The Life of Science – Sam
  • Edison Open House – Global Healthcare 2021 Interview
    Edison Open House – Global Healthcare 2021 Interview
  • Value in new medicines and ‘longer strides’
    Value in new medicines and ‘longer strides’
  • The Life of Science – Karen
    The Life of Science – Karen
Prev
Next

Footer

Resources

  • ASX Announcements
  • Investor Information
  • Board of Directors
  • News & Articles

Information

  • Contact
  • Partnering
  • Join Our Mailing List
  • Privacy, Terms and Conditions
  • Facebook
  • LinkedIn
  • Twitter
  • Vimeo
Copyright © 2021 · Exopharm · ACN 163 765 991 · info@exopharm.com
Level 17/31 Queen St, Melbourne VIC Australia 3000 · P: +61 (0)3 9111 0026 ·

Web Design by Mallee Blue Media